Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human growth hormone (RaniPill formulation RT-109)
- Development stage
- Preclinical
- Lead developer
- RANI Therapeutics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
RT-109 is the original RaniPill capsule, an investigational oral formulation developed by Rani Therapeutics to deliver human growth hormone (hGH) for the treatment of growth hormone deficiency[1]. Conventional hGH therapy requires daily subcutaneous injections, which are often painful; RT-109 aims to replace injections with oral administration by utilizing the proprietary RaniPill technology, which encapsulates the biologic agent in a capsule that survives stomach acid and releases its payload in the intestine for systemic absorption[1]. hGH is a protein hormone that stimulates growth, cell reproduction, and cell regeneration. Rani Therapeutics has entered into an Evaluation and First Right of Refusal agreement with Changchun High & New Technology Industries for commercialization rights in China[1].
- Other names
- human growth hormone (Rani therapeutics)hGH (RaniPill formulation RT-109)
02
Targets
GHR (Growth hormone receptor)
Beyond the preview
Go deeper on human growth hormone (RaniPill formulation RT-109).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human growth hormone (RaniPill formulation RT-109).